Royalty Pharma, whose $6.7 billion takeover bid for Elan Corp. lapsed this month, is holding internal discussions about making a new bid for the company with a partner, according to four people with knowledge of the situation.
Valeant Pharmaceuticals International Inc., Canada’s largest drugmaker, is close to acquiring Bausch & Lomb Holdings Inc., the eye-care company owned by Warburg Pincus LLC, for about $9 billion, said a person with knowledge of the negotiations.
After more than 40 years in business, Elan Corp. is “just starting,” says Chief Executive Officer Kelly Martin. The Irish drugmaker may prove more rewarding for investors in its second life than in the first.
DaimlerChrysler didn’t infringe patent owned by Laserfacturing Inc., a federal appeals court ruled yesterday. The dispute was over a method of welding using a laser or electron beam, covered by patent 5,595,670. The Washington-based U.S. Court of Appeals for the Federal Circuit said a Texas federal court had correctly interpreted the patent.
Allergan Inc. ’s Botox, the $1.4 billion drug known for smoothing facial wrinkles, will derive a dominating share of its revenue this year from therapeutic uses, such as chronic migraines, for the first time since 2006, Chief Executive Officer David Pyott said.